Combination chemotherapy with immunomodulatory agent

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

0 marketed 2 in Phase 3

This page covers all Combination chemotherapy with immunomodulatory agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Multiple targets: cereblon (thalidomide), DNA (melphalan), glucocorticoid receptor (prednisone).

Targets

Multiple targets: cereblon (thalidomide), DNA (melphalan), glucocorticoid receptor (prednisone)

Phase 3 pipeline (2)

Melphalan, Prednisone and Thalidomide · Gruppo Italiano Studio Linfomi · Oncology
This combination uses melphalan (alkylating agent) and prednisone (corticosteroid) as backbone chemotherapy with thalidomide (immunomodulatory agent) to kill myeloma cells and enhance immune response.
Thalidomide, Melphalan, Prednisone · Grupo de Estudos Multicentricos em Onco-Hematologia · Oncology
This combination uses thalidomide as an immunomodulatory agent, melphalan as an alkylating chemotherapy, and prednisone as a corticosteroid to treat multiple myeloma through multiple mechanisms including immune activation, DNA damage, and anti-inflammatory effects.

Patent intelligence

combination chemotherapy with immunomodulatory agent patent landscape — aggregated cliff calendar, attackable patents, originator estates